bioAffinity Technologies, Inc. (BIAF) AI Stock Analysis

• Market Cap: $7.75M
• Dividend Yield: N/A
• Average Volume (3M): 9.83M
• Price to Earnings (P/E): ―
• Beta (1Y): -2.21
• Revenue Growth: 78.40%
• EPS Growth: 22.41%
• Country: US
• Employees: 57
• Sector: Healthcare
• Sector Strength: 39
• Industry: Medical - Diagnostics & Research
• EPS (TTM): -0.16
• Shares Outstanding: 28,459,541
• 10 Day Avg. Volume: 21,909,312
• 30 Day Avg. Volume: 9,827,663
• PEG Ratio: 0.00
• Price to Book (P/B): -15.17
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -24.48
• Enterprise Value/Market Cap: 8.34
• Enterprise Value/Revenue: 1.86
• Enterprise Value/Gross Profit: 21.33
• Enterprise Value/Ebitda: -1.95
• 1Y Price Target: $6.00
• Price Target Upside: 2122.22% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 1

• Rating: 42 Neutral
• Price Target: $0.50 ▲(85.19%Upside)

The overall stock score for bioAffinity Technologies, Inc. is primarily driven by its weak financial performance, marked by negative profitability and high leverage. Technical analysis shows weak stock momentum, and valuation is poor due to a negative P/E ratio. While corporate events introduce some uncertainty, they provide a balance between potential compliance challenges and enhanced financial flexibility.

Positive Factors

Market Adoption

The number of physician offices offering the CyPath Lung test increased significantly, indicating growing adoption of the diagnostic test.

Product Expansion

The initial success of CyPath Lung in Texas has expanded to several other states through referrals and word-of-mouth, with expected momentum to continue through 2025.

Sales Growth

CyPath Lung sales were up 276% year-over-year, indicating strong growth potential despite some temporary setbacks.

Negative Factors

Capital Constraints

The company's capital constraints remain a concern, impacting the ability to operate profitably without raising additional funds.

Revenue Guidance

The company introduced 2025 revenue guidance significantly below prior estimates, leading to a downgrade of the stock to Hold.

Shareholder Impact

The company needs to raise additional capital immediately, which could lead to share dilution for current shareholders.

bioAffinity Technologies, Inc. Business Overview & Revenue Model

Company Description

bioAffinity Technologies, Inc., a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat cancer at the cellular level. The company was founded in 2014 and is based in San Antonio, Texas.

How the Company Makes Money

bioAffinity Technologies, Inc. generates revenue primarily through the commercialization of its diagnostic and therapeutic products. The company sells its products to healthcare providers, laboratories, and research institutions. Additionally, bioAffinity may enter into licensing agreements and partnerships with other biotechnology and pharmaceutical companies to co-develop or distribute its products, providing additional revenue streams. Research grants and funding from governmental and non-governmental organizations might also contribute to the company's earnings by supporting its research and development activities.

bioAffinity Technologies, Inc. Financial Statement Overview

Summary

BIAF faces significant financial challenges, with negative profitability and cash flow metrics. Despite some revenue growth, the company's high leverage and negative profit margins indicate financial instability. Improvements in operational efficiency and debt management are critical.

Income Statement

The income statement shows a volatile revenue growth with a significant increase from 2022 to 2023, but a decline in 2024. The company is struggling with negative profit margins, including gross profit, net profit, and EBITDA margins. The EBIT margin remains negative, reflecting operating inefficiencies and a challenging path to profitability.

Balance Sheet

The balance sheet indicates a high debt-to-equity ratio, suggesting substantial leverage, which could pose financial risks. However, there is a slight improvement in equity ratio over time. The company has been able to maintain positive stockholders' equity in recent periods after a negative balance in previous years.

Cash Flow

Cash flow analysis reveals consistent negative free cash flows, indicating challenges in generating cash from operations. The operating cash flow to net income ratio is negative, reflecting cash burn. However, free cash flow to net income improved slightly in recent periods, showing potential for future cash efficiency.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	8.81M	9.36M	2.53M	4.80K	0.00	0.00
Gross Profit	3.03M	3.38M	791.62K	4.34K	-4.82K	-22.24K
EBITDA	-9.03M	-8.33M	-7.63M	-5.61M	-2.20M	-6.86M
Net Income	-9.74M	-9.04M	-7.94M	-8.15M	-6.33M	-7.27M
Balance Sheet
Total Assets	5.55M	6.51M	8.22M	12.18M	1.45M	145.60K
Cash, Cash Equivalents and Short-Term Investments	444.71K	1.11M	2.82M	11.41M	1.36M	83.11K
Total Debt	1.33M	1.50M	1.58M	251.75K	11.36M	10.01M
Total Liabilities	4.11M	3.91M	3.37M	1.14M	17.24M	15.22M
Stockholders Equity	1.44M	2.60M	4.86M	11.04M	-15.79M	-15.07M
Cash Flow
Free Cash Flow	-6.65M	-7.34M	-6.06M	-4.29M	-2.05M	-2.21M
Operating Cash Flow	-6.56M	-7.26M	-6.04M	-4.07M	-2.05M	-2.21M
Investing Cash Flow	-88.48K	-79.08K	-2.21M	-219.99K	0.00	-2.89K
Financing Cash Flow	4.64M	5.63M	-344.98K	14.34M	3.33M	1.72M

bioAffinity Technologies, Inc. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.27
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BIAF, the sentiment is Negative. The current price of 0.27 is below the 20-day moving average (MA) of 0.28, below the 50-day MA of 0.30, and below the 200-day MA of 0.84, indicating a bearish trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 47.88 is Neutral, neither overbought nor oversold. The STOCH value of 20.90 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for BIAF.

bioAffinity Technologies, Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
PRPO	65 Neutral	$18.22M	―	-25.29%	―	26.67%	44.02%
INBS	62 Neutral	$12.30M	―	-126.34%	―	3.87%	91.76%
Sector *	52 Neutral	$7.50B	0.31	-61.87%	2.27%	17.10%	1.59%
TRIB	49 Neutral	$13.94M	―	77.20%	―	8.31%	9.98%
BIAF	42 Neutral	$7.75M	―	-290.85%	―	78.40%	22.41%
BNGO	41 Neutral	$11.34M	―	-127.82%	―	-24.04%	84.11%
MYNZ	41 Neutral	$5.46M	―	-809.29%	―	―	―

bioAffinity Technologies, Inc. Corporate Events

bioAffinity Receives Nasdaq Non-Compliance Notice

On May 27, 2025, bioAffinity Technologies, Inc. received a notice from Nasdaq indicating non-compliance with the stockholders’ equity requirement of $2,500,000, as their equity was reported at $1,439,404 as of March 31, 2025. The company plans to submit a compliance plan by July 11, 2025, to address this issue and maintain its listing on the Nasdaq Capital Market. The notification does not immediately affect the company’s listing, and they are exploring options to regain compliance, although acceptance of the plan by Nasdaq is not guaranteed. This notice is separate from a previous deficiency related to the minimum bid price requirement.

The most recent analyst rating on (BIAF) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on bioAffinity Technologies, Inc. stock, see the BIAF Stock Forecast page.

bioAffinity Technologies Enters Sales Agreement with WallachBeth

On May 22, 2025, bioAffinity Technologies, Inc. entered into an At-The-Market Issuance Sales Agreement with WallachBeth Capital LLC to facilitate the sale of its common stock through an ‘at the market offering’ program. This agreement allows the company to sell shares directly on the Nasdaq Capital Market or other trading platforms, with WallachBeth acting as the sales agent. The agreement provides flexibility in terms of the number of shares sold and the timing, while also allowing for termination by either party under certain conditions. The arrangement is expected to enhance the company’s financial flexibility and market presence.

The most recent analyst rating on (BIAF) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on bioAffinity Technologies, Inc. stock, see the BIAF Stock Forecast page.

bioAffinity Technologies Sets 2025 Annual Meeting Date

bioAffinity Technologies, Inc. has announced plans for its 2025 Annual Meeting of Stockholders, which will take place on July 25, 2025. The company has set the record date for determining stockholders entitled to vote at the meeting as May 29, 2025. Due to the meeting being scheduled more than 30 days after the previous year’s meeting, revised deadlines for stockholder proposals have been provided. Proposals under Rule 14a-8 must be submitted by May 26, 2025, while notices for director nominations must comply with Rule 14a-19 by May 29, 2025.

The most recent analyst rating on (BIAF) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on bioAffinity Technologies, Inc. stock, see the BIAF Stock Forecast page.

bioAffinity Technologies Completes $3.2M Public Offering

On May 7, 2025, bioAffinity Technologies, Inc. completed a public offering of common stock and warrants, raising approximately $3.2 million in gross proceeds. The company plans to use the funds for working capital and general corporate purposes. The offering included agreements that restrict the issuance of additional shares for a specified period, which may impact the company’s market activities and shareholder interests.

bioAffinity Technologies Board Member Announces Departure

On April 12, 2025, Stuart Diamond, a board member of bioAffinity Technologies, Inc., announced he will not seek re-election at the company’s 2025 annual stockholders’ meeting. His decision was not due to any disagreements with the company’s operations or policies.